Guardant Health, Inc. (GH)
After hours:
| Previous close | 44.46 |
| Open | 44.76 |
| Bid | 43.63 x 900 |
| Ask | 48.67 x 1800 |
| Day's range | 44.02 - 46.27 |
| 52-week range | 27.65 - 133.82 |
| Volume | |
| Avg. volume | 1,488,327 |
| Market cap | 4.702B |
| Beta (5Y monthly) | 0.66 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture
PALO ALTO, Calif., June 13, 2022--Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it has purchased the remaining shares of Guardant Health AMEA, Inc., held by SoftBank and its affiliates, giving the company full control over operations throughout the Asia, Middle East and Africa region.
- Business Wire
Guardant Health to Participate in Upcoming June Investor Conferences
REDWOOD CITY, Calif., May 26, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.
- Business Wire
First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d’Hebron Institute of Oncology
PALO ALTO, Calif. & BARCELONA, Spain, May 25, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and the Vall d’Hebron Institute of Oncology (VHIO), one of Europe’s leading cancer research organizations, today announced that the first blood-based cancer testing services in Europe based on Guardant Health’s industry-leading digital sequencing platform are now available at the VHIO liquid biopsy testing facility in Barcelona.
